Prenatal screening and testing can be a part of perinatal care that allows couples to have information about their babies' health status before birth to manage the pregnancy and make decisions beforehand (Ravitsky, 2017). While prenatal screening assesses a pregnant woman's chance of having a fetus affected by a genetic condition, prenatal testing (or diagnostic testing) determines whether the fetus has a specific genetic condition. The diagnosis of a fetus with a genetic condition allows the couple to make an informed decision on the management of their pregnancy. If a genetic condition is identified, pregnancy termination may be planned by choice (Krstić & Obićan, 2020;Ravitsky, 2017), or the couple may have gained time to optimize neonatal outcomes by determining the appropriate facility for delivery and essential healthcare professionals for the care of the baby (American College of Obstetricians & Gynecologists, 2016). According to the American College of Obstetricians and Gynecologists, several prenatal screening tests are available in the first and/or second trimester during the pregnancy. The firsttrimester screening test consists of three markers, including maternal serum beta-human chorionic gonadotropin (beta-hCG), maternal serum pregnancy-associated plasma protein-A (PAPP-A), and nuchal translucency (NT) measurement. The combined test consists of these markers, and together with maternal age, it provides a patient-specific risk. The second-trimester quadruple test includes alpha-fetoprotein (AFP), beta-hCG, estriol, and inhibin A (Krstić & Obićan, 2020). The quadruple test is the most common test used for women who had their first prenatal care in the second trimester or decide to undergo screening in the second trimester (Krstić & Obićan, 2020). There are also integrated tests that use markers measured in both first and second trimesters to estimate the chance for Down syndrome. These test options have different detection and false-positive rates. Integrated tests have the advantage of